Job Board drug-testing-news advertise-with-us1

Articles

BREAKING NEWS - DTAB RECOMMENDATIONS APPROVED BY HHS!

Recently, the Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) Administrator Pamela S. Hyde, J.D. approved both of the Drug Testing Advisory Board (DTAB) July, 2011, recommendations:

(1) Based on review of the science, DTAB recommends that SAMHSA include oral fluid as an alternative specimen in the Mandatory Guidelines for Federal Workplace Drug Testing Programs.

(2) DTAB recommends the inclusion of additional Schedule II prescription medications (e.g., oxycodone, oxymorphone, hydrocodone and hydromorphone) in the Mandatory Guidelines for Federal Workplace Drug Testing Programs.

The Department of Transportation's (DOT) Office of Drug and Alcohol Policy and Compliance (ODAPC) stated, "the opportunity to address the illicit use and abuse of these additional Schedule II drugs in the transportation industries is an important way to limit their misuse in our communities and a great way to serve transportation safety, while getting those who need treatment into treatment. And please know that oral fluid testing will be a bonus to our regulated transportation industry program; and will certainly serve to assist the DOTs National Highway Traffic Safety Administration in its efforts, with others, to establish national per se laws for Driving Under the Influence of Drugs (DUID)."

DOT is required by law to follow HHS procedures for the drugs for which they test and the specimens they test. Therefore, the DOT will continue to work with the DTAB, HHS/SAHMSA, the Office of National Drug Control Policy, and others to bring these approved recommendations to realization in our regulations and throughout the transportation industries


Sponsors

  • Alere Toxicology
  • Intoximeters
  • Oral Eze
  • PAS Systems International
  • NDT
  • Quest Diagnostics
  • EMSI
Previous Next

Login

Media Info
 Laura Shelton, CMP
This email address is being protected from spambots. You need JavaScript enabled to view it.  
 800-355-1257 ext. 40